1. Home
  2. REX vs DRTS Comparison

REX vs DRTS Comparison

Compare REX & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REX American Resources Corporation

REX

REX American Resources Corporation

N/A

Current Price

$43.75

Market Cap

1.4B

Sector

Industrials

ML Signal

N/A

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

N/A

Current Price

$14.51

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REX
DRTS
Founded
1980
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
REX
DRTS
Price
$43.75
$14.51
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $17.80
AVG Volume (30 Days)
166.7K
★ 443.8K
Earning Date
09-02-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.62
N/A
Revenue
★ $650,487,000.00
N/A
Revenue This Year
$18.22
N/A
Revenue Next Year
N/A
$1,235.59
P/E Ratio
$26.51
★ N/A
Revenue Growth
★ 1.24
N/A
52 Week Low
$30.31
$3.43
52 Week High
$53.36
$15.79

Technical Indicators

Market Signals
Indicator
REX
DRTS
Relative Strength Index (RSI) 49.39 51.78
Support Level $41.76 $13.73
Resistance Level $44.58 $15.01
Average True Range (ATR) 1.22 0.59
MACD 0.07 -0.07
Stochastic Oscillator 47.96 40.18

Price Performance

Historical Comparison
REX
DRTS

About REX REX American Resources Corporation

REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: